share_log

君聖泰醫藥-B：君聖泰完成HTD1801治療2型糖尿病的III期臨床試驗患者入組

HIGHTIDE-B: HIGHTIDE COMPLETES PATIENT ENROLLMENT OFPHASE III CLINICAL TRIALS OF HTD1801 FORTHE TREATMENT OF TYPE 2 DIABETES MELLITUS

Hong Kong Stock Exchange ·  Jun 27 08:11
Summary by Moomoo AI
君聖泰醫藥-B（股份代號：2511.HK）宣布其自主研發的HTD1801治療2型糖尿病的兩項III期臨床註冊試驗已完成患者入組。這兩項試驗分別為SYMPHONY-1和SYMPHONY-2，旨在評估HTD1801對2型糖尿病患者的糖化血紅蛋白及葡萄糖代謝等指標的影響。HTD1801是一種新型口服腸肝抗炎及代謝調節劑，目前中國是全球2型糖尿病患者最多的國家，HTD1801的開發對於滿足未被滿足的醫療需求具有重要意義。君聖泰醫藥是一家專注於開發多功能多靶點療法的全球生物製藥公司，HTD1801已獲得美國FDA的快速通道資格認定及孤兒藥資格認定，並在中國獲得重大新藥創制科技專項。公司提醒股東及潛在投資者，HTD1801的成功開發並上市仍存在不確定性，投資時需謹慎。
君聖泰醫藥-B（股份代號：2511.HK）宣布其自主研發的HTD1801治療2型糖尿病的兩項III期臨床註冊試驗已完成患者入組。這兩項試驗分別為SYMPHONY-1和SYMPHONY-2，旨在評估HTD1801對2型糖尿病患者的糖化血紅蛋白及葡萄糖代謝等指標的影響。HTD1801是一種新型口服腸肝抗炎及代謝調節劑，目前中國是全球2型糖尿病患者最多的國家，HTD1801的開發對於滿足未被滿足的醫療需求具有重要意義。君聖泰醫藥是一家專注於開發多功能多靶點療法的全球生物製藥公司，HTD1801已獲得美國FDA的快速通道資格認定及孤兒藥資格認定，並在中國獲得重大新藥創制科技專項。公司提醒股東及潛在投資者，HTD1801的成功開發並上市仍存在不確定性，投資時需謹慎。
Kingsmed Biopharma-B (stock code: 2511.HK) announced that the two phase III clinical registration trials of its self-developed HTD1801 for the treatment of type 2 diabetes have completed patient enrollment. These two trials, SYMPHONY-1 and SYMPHONY-2, aim to evaluate the effect of HTD1801 on glycated hemoglobin and glucose metabolism indicators of type 2 diabetes patients. HTD1801 is a new type of oral intestinal and hepatic anti-inflammatory and metabolic regulator. Currently, China has the largest number of type 2 diabetes patients in the world, and the development of HTD1801 is of great significance in meeting the unmet medical needs. Kingsmed Biopharma is a global biopharmaceutical company dedicated to developing multifunctional and multi-targeted therapies. HTD1801 has obtained the qualification of fast track and orphan drug from the US FDA, and the major new drug creation science and technology project in China. The company reminds shareholders and potential investors that there is still uncertainty in the successful development and launch of HTD1801, and caution is needed when investing.
Kingsmed Biopharma-B (stock code: 2511.HK) announced that the two phase III clinical registration trials of its self-developed HTD1801 for the treatment of type 2 diabetes have completed patient enrollment. These two trials, SYMPHONY-1 and SYMPHONY-2, aim to evaluate the effect of HTD1801 on glycated hemoglobin and glucose metabolism indicators of type 2 diabetes patients. HTD1801 is a new type of oral intestinal and hepatic anti-inflammatory and metabolic regulator. Currently, China has the largest number of type 2 diabetes patients in the world, and the development of HTD1801 is of great significance in meeting the unmet medical needs. Kingsmed Biopharma is a global biopharmaceutical company dedicated to developing multifunctional and multi-targeted therapies. HTD1801 has obtained the qualification of fast track and orphan drug from the US FDA, and the major new drug creation science and technology project in China. The company reminds shareholders and potential investors that there is still uncertainty in the successful development and launch of HTD1801, and caution is needed when investing.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more